State Privacy Laws Bringing HIPAA-Style Safeguards to Wearable Health Data

Picture this: Over a third of Americans strap on a wearable—whether it’s an Apple Watch tracking heart rhythms or an Oura ring monitoring sleep cycles—chasing smarter wellness routines. These gadgets pull in intimate details like blood oxygen reads, fall alerts, respiration rates, VO2 max scores, and even EEG brain waves from advanced models. But here’s the rub: Unlike traditional healthcare providers, the tech firms behind these devices aren’t bound by HIPAA. That means no mandatory de-identification before hawking anonymized data to advertisers or partners.

Federal lawmakers have talked a big game, but gridlock has stalled comprehensive reform. Enter the states, racing to plug the holes with rules that treat health data as ultra-sensitive. Knowing how these patchwork protections are nudging businesses toward HIPAA-inspired de-identification practices is important to building out a refined data governance posture for your company if you’re in the health-tech space. So, whether you’re a wearable maker, app developer, or ad platform, here’s the lay of the land—and how to gear up to meet privacy compliance measures with our help.

Federal Foot-Dragging Meets State Action

Congress has mulled bills to rope in consumer tech under HIPAA-like rules, but nothing’s stuck—until now. On November 4, 2025, Sen. Bill Cassidy (R-La.) dropped the Health Information Privacy Reform Act (S.3097), a bipartisan push to extend federal privacy baselines to wearables and health apps. It would mandate consent for data shares, beef up breach notifications, and require de-identification for secondary uses, mirroring HIPAA’s safe harbor or expert methods. Still early days: The bill’s in committee, with hearings eyed for early 2026.

Without a national fix, states are leading the charge. All 19 with comprehensive privacy laws flag “consumer health data” as sensitive, triggering extras like opt-ins or sale bans. (That’s up from 18 earlier this year, with Nevada’s tweaks.) These split into two camps: narrow scopes in nine states and broader ones in ten, plus Washington’s outlier standalone act. The variance? It could mean the difference between routine opt-outs and full-throated consents for your data playbook.

Narrow Definitions: Room to Maneuver for Wearables

On the lighter-touch side, several comprehensive-privacy states, including Indiana, Iowa, Kentucky, Nebraska, Tennessee, Texas, and Virginia, define sensitive health data around a mental or physical health diagnosis. Minnesota and Montana are broader: each covers personal data revealing a mental or physical health condition or diagnosis, so inferred conditions are not automatically outside sensitive-data treatment. If your wearable sticks to fitness metrics without “diagnosing” (say, flagging arrhythmia as a condition), you might dodge sensitive status. Heart rate spikes? Still personal data, so users get access, deletion, and targeted ad opt-outs—but no opt-in wall.

This carve-out buys breathing room for non-medical apps, but tread carefully: Regulators could stretch “diagnosis” to inferred insights, like AI spotting sleep apnea from patterns. Texas treats a mental or physical health diagnosis as sensitive data under the Texas Data Privacy and Security Act. Official Texas Attorney General announcements do not describe a 2025 fitness-tracker probe that rejected claims of overreach.

Broad Strokes: Heart Rates and Beyond as Sensitive

Flip to the ten broader states—California, Colorado, Connecticut, Delaware, Maryland, New Hampshire, New Jersey, Oregon, Rhode Island, and Utah—and the net widens to any “status, condition, or health-related info.” That sweeps in wearable staples: wrist temps, VO2 trends, even stress inferred from variability. Except in California (opt-out model), these demand explicit opt-in consent for collection, processing, or sharing.

Compliance hit: For cross-state ops, default to opt-in banners at signup, with granular toggles. Colorado’s Privacy Act treats data revealing a mental or physical health condition or diagnosis as sensitive data and generally requires consent before that processing. Public Colorado Attorney General announcements do not identify a 2025 $2.3 million meditation-app consent fine.

The Neural Data Puzzle: Brain Waves Under the Microscope

Edgier still: Neural signals like EEG from sleep headbands. Do they count as “health data”? It’s murky, but three states say yes outright—California, Colorado, and Connecticut explicitly list neural data in their definitions. Montana folds it into its Genetic Information Privacy Act, though likely just for DNA-tied firms.

For the broad-definition crew, AGs could argue EEG reveals mental states (anxiety patterns, say), demanding opt-ins. Jameson Spivak’s 2025 analysis flags Colorado’s biometric tie-in: It kicks in only if the device IDs the user. Open bet: In a test case, New Jersey’s AG might probe a neurofeedback wearable, citing “condition” coverage. Businesses: Flag neural features early, layer consents, and pseudonymize where possible.

The Heavy Hitters: Washington and Maryland Lead the Charge

Then come the strictest: Washington’s My Health My Data Act (MHMDA, effective 2024) casts the widest net, deeming any “consumer health data” (from wellness tips to symptom logs) regulable, with private rights of action for violations. No small-business coverage threshold like those in comprehensive state privacy laws: collection and sharing generally require opt-in consent for a specified purpose, or must be necessary to provide a product or service the consumer requested. The Act does not set an 18-month retention cap.

Maryland’s Online Data Privacy Act (ODPA, 2025) dials it to 11: It outright bans selling or targeted ads based on sensitive health data, consent be damned. “Sale” includes any monetized share, so adtech tie-ins? Off-limits. Both likely snag neural data; Washington’s My Health My Data Act is enforced through the Consumer Protection Act and has been the basis for private suits, but official sources do not identify a 2025 Washington $5 million fertility-tracker settlement.

Pending Power Plays: Eyes on Massachusetts and New York

The momentum’s building. Massachusetts’ H.4746 (Massachusetts Consumer Data Privacy Act), released November 17, 2025, by the House Committee, echoes some of Maryland’s toughness on sensitive data: H.4746 would ban the sale of precise geolocation data and allow other sensitive-data sales only with the consumer’s affirmative consent. The House later substituted and passed a different bill (H.5479) on June 4, 2026; the Senate non-concurred, a conference committee was appointed, and no comprehensive Massachusetts consumer data-privacy act was enacted before formal sessions of the 194th General Court ended on July 31, 2026.

New York’s Senate Bill 929 (the Health Information Privacy Act) passed both chambers in January 2025 and was vetoed by Governor Hochul on December 19, 2025. It did not become law. A later revised bill has been introduced; New York still has no standalone comprehensive health-information privacy act of that kind. This would vault NY into the standalone health privacy club, hitting wearables hard.

De-Identification: Your HIPAA-Inspired Shield

For ad-driven models, the endgame? De-identify before sharing. Every U.S. privacy law so far carves out truly anonymized data—no re-identification risk, no rules apply. Contrast GDPR: Pseudonymized counts as personal, needing DPIAs.

Borrow HIPAA’s toolkit: Safe harbor strips 18 identifiers (names, IPs, etc.), or expert stats certify low risks. For wearables, aggregate trends (e.g., city-wide VO2 averages) sans geofencing. Washington’s MHMDA nods to this, exempting de-ID’d sets. Pro: Scales nationally. Con: Re-ID tech (like Apple’s differential privacy) evolves fast—audit yearly.

Steering Through the Maze: Action Items for Your Team

As states harmonize toward HIPAA-lite, non-compliance risks CCPA administrative fines and civil penalties of up to $2,663 per violation, or $7,988 for intentional violations and violations involving consumers the business knows are under 16, as well as class actions under other statutes. Quick wins:

• Map Data Flows: Tag health metrics by state—narrow vs. broad.
• Consent Overhaul: Granular opt-ins for broad states; test UI for clarity.
• De-ID Playbook: Adopt HIPAA methods; third-party certify.
• Monitor Feds: Track Cassidy’s HIPRA for preemptive alignment.
• Audit Partners: Vet adtech for downstream compliance, especially neural adds.

These shifts aren’t just hurdles—they’re chances to build trust and sidestep 23andMe-style breaches (that 2023 hack still echoes in suits). At Captain Compliance, we craft bespoke roadmaps and privacy solutions to keep your business compliant. Let’s chat: Book a privacy software demo and future-proof your health tech edge with the help of Captain Compliance today.